Mycotopia Therapies Inc - TPIA STOCK NEWS

AIBotics, a subsidiary of Ehave (EHVVF), has signed a letter of intent to acquire DigiTrax Entertainment in a $40 million transaction. The deal includes seven U.S. patents in music AI, a $9 million music catalog, and licensing agreements with leading publishers. DigiTrax's last funding round valued the company at $32 million.

The acquisition, targeted to close by February 28, 2025, will position DigiTrax as an AIBotics subsidiary. DigiTrax shareholders will receive newly designated preferred stock, common stock, and cash consideration. DigiTrax CEO Joseph Vangieri will retain his position and join AIBotics' board.

DigiTrax operates through three divisions: AI Innovation (featuring the KR38R platform), Karaoke Interactive Digital Media Platform, and Music Catalog Services. The company's AI technology is integrated with major digital audio workstations and has been adopted by platinum artists and major labels.

AIBotics (OTC: TPIA) provided an update on its 2024 achievements and 2025 strategic vision. The company, formerly Mycotopia Therapies, has focused on AI and robotics in wellness and healthcare following the acquisition of Philon Labs. Key developments include their flagship products: Phill Robot™, an AI-powered massage robot that achieved 100% of its crowdfunding goal in 24 minutes, and MilkyWay, an innovative breast milk storage system awarded 'Patent of the Month'.

The company has filed with FINRA to change its name and ticker symbol, reflecting its new strategic direction. Phill Robot™ development milestones include enhanced manufacturing design, high-fidelity prototypes, and advanced AI features. The global massage equipment market is valued at $23.86 billion (2023) with projected growth to $41.18 billion by 2032.

Mycotopia Therapies Inc. (OTC: TPIA) has acquired certain assets of Philon Labs, LLC, including patents for AI robotics-based home health products. The acquisition marks the company's transition to a growth-oriented entity focused on AI-enhanced products. The patents relate to the 'Milkyway' smart fridge for breast milk storage bags and the 'Phill Robot' massage robot, both utilizing advanced AI technology. Mycotopia Therapies will rebrand as AiBotics and change its trading symbol to ABIT. The acquisition involves issuing new class of Preferred Stock valued at $2,000,000 convertible into shares of the Common Stock of Mycotopia.

Ei.Ventures and Mycotopia Therapies (OTC: TPIA) announced the termination of their merger agreement with PSLY.com, Inc., which was initially established on May 17, 2022. The decision to end the merger, effective February 16, 2023, stems from unfavorable market conditions and the belief that this timing does not optimize shareholder value. Following this, PSLY.com will withdraw its SEC filing and discontinue its NASDAQ listing application. Both CEOs expressed disappointment but acknowledged the necessity of this decision in the current economic landscape.

Mycotopia Therapies Inc. (TPIA) announced a merger with Ei.Ventures Inc., forming PSLY.com and targeting a NASDAQ listing. The merger values Ei at approximately $360 million and Mycotopia at over $23 million. Upon completion, PSLY.com will have a market value of $383 million. The companies aim to leverage their combined resources in legal psilocybin markets, enhancing product offerings like Odyssey Elixir and Psilly patches. The transaction is expected to close around July 30, 2022.

Mycotopia Therapies (TPIA) and Ei.Ventures have announced strategic investments to advance their business plan, focusing on plant-based psychedelic therapies. The combined entity, renamed PSLY.COM, aims to develop botanical psychedelic APIs and therapeutics, differentiating itself from competitors focused on synthetic drugs. Key investments include $1.111 million in Avicanna and Odyssey Elixir, supporting their growth in the psychedelic market. As they approach a $360 million public transaction, both companies emphasize their commitment to mental wellness through natural therapies and Web 3.0 integration.

Mycotopia Therapies Inc. (OTC Pink: TPIA) has announced a partnership with PsychedelicsEUROPE to enhance psychedelic research and develop regulatory frameworks for medicinal use in Europe. The collaboration is driven by the increasing acceptance of psychedelic medicine for treating mental health issues, particularly depression. CEO Ben Kaplan highlighted the potential for transformative patient treatments and ongoing acquisition efforts for Ei.Ventures to expand their psychedelic assets.

Mycotopia Therapies (OTC Pink: TPIA) is advancing plans to enter the $13 billion medicinal mushroom market through the formation of PSLY.COM with Ei.Ventures. The company will utilize HAVN Life Sciences's functional mushrooms in its MANA product line, aimed at consumers. Mycotopia will also acquire a $2.2 million virtual estate in The Sandbox, bolstering its metaverse presence. Following the acquisition of Ei.Ventures, PSLY.COM intends to pursue a NASDAQ listing and focus on therapeutic and non-psychoactive mushroom nutraceuticals, targeting significant growth in the mushroom and telepsychiatry markets.

Mycotopia Therapies (OTC Pink: TPIA) has expanded its supply agreement with Havn Life Sciences to include functional mushrooms, enhancing its distribution capabilities for naturally-derived psilocybin and OTC health products in Jamaica. The Jamaican Ministry of Health is involved in the registration of these products. Mycotopia also plans to combine its resources with Ei.Ventures for developing psilocybin therapies, with the goal of addressing global mental healthcare needs. The collaboration is expected to alleviate supply chain issues and facilitate revenue generation.